Dr. Maleki’s research is focused on understanding how to sensitize hard-to-treat cancers to immunotherapy with immune checkpoint inhibitors. Dr. Maleki’s main focus is to induce neoantigen formation in tumor cells by blocking their DNA repair pathways.

Dr. Maleki is also interested in translating promising pre-clinical Immuno-Oncology studies into early phase I clinical studies. He collaborates with medical oncologists, surgical oncologists, and radiation oncologists at the London Regional Cancer Program to organize such early clinical studies. Dr. Maleki is currently leading a multidisciplinary team of clinicians and scientists that are organizing a phase I study on combination of Fecal Microbial Transplant (FMT) with immunotherapy in melanoma patients.

Dr. Maleki’s is a member of the city-wide melanoma/skin disease site team and Immunotherapy Tumor Board. His clinical interest also involves renal cell carcinoma, head and neck cancer, lung cancer, and breast cancer.